Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly-ICLC Adjuvant for NY-ESO-1 Vaccine in Melanoma
NCT01079741Phase 2Completed
- Sponsor
- Nina Bhardwaj
- Start
- Sep 2010
- Primary completion
- Mar 2013
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of poly iclc in melanoma, sponsored by Nina Bhardwaj. Started Sep 2010; status: completed.
02
Drugs
poly iclc
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01079741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01079741.